BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 7995947)

  • 21. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
    Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
    Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
    Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
    Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
    Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
    In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model.
    Ambade A; Mulherkar R
    Cancer Lett; 2008 Dec; 272(2):316-24. PubMed ID: 18762367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.
    Heo DS; Snyderman C; Gollin SM; Pan S; Walker E; Deka R; Barnes EL; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1989 Sep; 49(18):5167-75. PubMed ID: 2766286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
    Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
    Lee JM; Yoon SH; Kim HS; Kim SY; Sohn HJ; Oh ST; Oh IH; Kim TG
    Cancer Gene Ther; 2010 Oct; 17(10):742-50. PubMed ID: 20559334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
    Gallinger S; Hoskin DW; Mullen JB; Wong AH; Roder JC
    Cancer Res; 1990 Apr; 50(8):2476-80. PubMed ID: 2138507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.
    Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Zanovello P; Collavo D
    Br J Cancer; 1999 Mar; 79(7-8):1067-73. PubMed ID: 10098738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft.
    Zhang J; Sun R; Wei H; Tian Z
    Int Immunopharmacol; 2005 Feb; 5(2):417-25. PubMed ID: 15652770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis.
    Johansson BR; Unger ML; Albertsson P; Casselbrant A; Nannmark U; Hokland M
    Nat Immun; 1996-1997; 15(2-3):87-97. PubMed ID: 9162267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity.
    Matsumoto G; Nghiem MP; Nozaki N; Schmits R; Penninger JM
    J Immunol; 1998 Jun; 160(12):5781-9. PubMed ID: 9637488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.
    Sumareva R; Ukrainsky G; Kiremidjian-Schumacher L; Roy M; Wishe HI; Steinfeld AD; Cooper JS
    Radiat Oncol Investig; 1999; 7(1):22-9. PubMed ID: 10030620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.